Claim Missing Document
Check
Articles

Found 2 Documents
Search

Analysis of Vitamin D Levels on Bronchiectasis Severity Yacob Arawamin Batkunde; Muhammad Ilyas; Irawaty Djaharuddin; Nur Ahmad Tabri; Harun Iskandar; Arif Santoso
Respiratory Science Vol. 1 No. 2 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i2.11

Abstract

Background: Bronchiectasis is a chronic disease caused by repeated infection and inflammation of the bronchial walls. Vitamin D plays a role secretion of antimicrobial peptide and inhibits release of pro-inflammatory cytokines in the lungs. Vitamin D deficiency is associated with exacerbations, severity and decreased lung function in bronchiectasis. Several studies have found an association between vitamin D levels and bronchiectasis severity. Methods: This study used cross-sectional study design with consecutive sampling method on bronchiectasis patients who enrolled outpatient and inpatient at Wahidin Sudirohusodo hospital in February - May 2020. All research procedures obtained the approval of the Health Research Ethics Commission, Medicine faculty, Hasanuddin University Makassar. Bronchiectasis severity was assessed based on the FACED score (FEV1, Aged, chronic Colonization by Pseudomonas aeuroginosa, radiological Extension of the disease, Dyspnea). Levels of vitamin D serum {25 (OH) D} were checked using the ELISA method. Results: The study subjects were 44 patients, consisting of 61.4% male and 38.6% female. Most of the bronchiectasis patients in this study were mild (77.3%) based on the FACED score, 15.9% moderate and 6.8% severe. As many as 77.3% of patients had vitamin D deficiency and insufficiency as much as 9.1%. All patients with moderate-severe FACED scores had vitamin D deficiency. The correlation between vitamin D levels and FACED scores showed a positive significant with p-value 0.04. Conclusion: Low vitamin D levels are a risk factor for aggravating bronchiectasis severity and have a positive significant correlation between the two.
Association Between PAI-1 4G/5G Genetic Polymorphism and Uncontrolled Allergic Asthma Harun Iskandar; Muh Ilyas; Eliana Muis; Nur Ahmad Tabri; Dewi Setiawati
Advance Sustainable Science Engineering and Technology Vol. 7 No. 3 (2025): May - July
Publisher : Science and Technology Research Centre Universitas PGRI Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26877/asset.v7i3.1872

Abstract

Airway remodeling is a major challenge in the management of uncontrolled allergic asthma, despite standard therapy with a combination of inhaled corticosteroids (ICS) and long-acting bronchodilators (LABA). Increased levels of Plasminogen Activator Inhibitor-1 (PAI-1) are thought to play a role in this process, and the 4G/5G polymorphism in the PAI-1 gene is one of the genetic factors that affect it. This study aimed to analyze the association between the 4G/5G PAI-1 genetic polymorphism and uncontrolled allergic asthma. A case-control study was conducted at Wahidin Sudirohusodo General Hospital between January-March 2024 on 40 patients with allergic asthma and 40 non-asthmatic subjects. Diagnosis was made through prik test (+), bronchodilator test (+), and asthma control classification according to GINA criteria. All asthmatic patients received Budesonide-Formoterol therapy for 4 weeks. PAI-1 levels were measured and 4G/5G polymorphism was analyzed by RT-PCR. Results showed that PAI-1 levels were significantly higher in uncontrolled asthma patients and in individuals with the 4G/4G genotype compared to non-4G/4G (2.38 ± 0.770 vs 1.65 ± 0.714; p=0.001). The 4G/4G genotype was more common in uncontrolled asthma (OR: 5.8) and was associated with the risk of severe obstruction (OR: 11.6). Thus, it was concluded that the 4G/4G genotype in the PAI-1 gene is associated with increased PAI-1 levels, risk of uncontrolled allergic asthma, and more severe degree of airway obstruction. The implication of the results shows that genetic testing of PAI-1 has the potential to be a predictive biomarker in personalized asthma therapy strategies. This approach can help clinicians identify high-risk patients and tailor interventions early and effectively to prevent remodeling and reduce long-term morbidity.